Company Overview
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company focused on developing specialized medical therapies. The firm is situated within the healthcare sector, specifically functioning in the medical devices industry, where it aims to address critical unmet medical needs through its drug pipeline. The company currently maintains a market capitalization of $2.35M, generates $482,000 in annual revenue, and employs a workforce of 7 individuals. These financial and operational metrics indicate that the company functions on a micro-cap scale, characterized by significant revenue limitations relative to its cash reserves and a very small operational footprint. The disparity between its modest revenue of less than half a million dollars and its substantial cash holdings suggests the business is in a pre-commercialization or early clinical development phase where capital preservation is prioritized over immediate profit generation. The limited employee count of 7 further underscores the lean organizational structure typical of late-stage biotechnology firms attempting to advance a single lead asset without large-scale manufacturing operations.
Financial Health
The company reported revenue of $482,000 over the trailing twelve months, yet it recorded a net income loss of $-7,553,000 and an EBITDA of $-7,404,000. The substantial negative gap between the $482,000 in revenue and the $-7,553,000 in net income reveals an extremely aggressive cost structure where operating expenses significantly exceed all income streams. This financial profile is typical of a research-intensive entity where development costs for lead drug candidates like Entolimod consume the majority of available capital. Free cash flow stands at $-3,576,750, indicating that the company is burning through its liquidity to fund its development efforts rather than generating cash from operations. Despite these outflows, the balance sheet shows $3.45M in cash and N/A for debt, creating a scenario where the company is not leveraged but is strictly dependent on external funding to sustain operations. The gross margin is listed at -58.1%, the operating margin is -1700.7%, and the profit margin is 0.0%, all of which reflect the high burn rate inherent in late-stage clinical trials where costs are high but sales are negligible. The current ratio is 5.86, which indicates that the company possesses ample short-term liquidity to cover its current liabilities even while operating at a loss. Return on Equity is -178.2% and Return on Assets is -96.2%, metrics that reveal that management is currently unable to generate positive returns on the capital invested or the assets held, a common characteristic for companies in the late-stage development phase before product approval.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed as -0.04, implying that the market is currently pricing the stock without an expectation of immediate profitability or based on negative earnings projections. The price-to-book ratio stands at 0.28, indicating that the market values the company at a fraction of its book value, which often suggests that the market perceives significant risk or that the assets held (primarily cash) are not fully capitalized in the stock price. The price-to-sales ratio is 4.87 and the EV/EBITDA is 0.24, alternative metrics that suggest the valuation is heavily weighted toward sales potential rather than earnings power, given the negative EBITDA. The stock has a 52-week high of $13.23 and a 52-week low of $0.72, creating a trading range where the current price sits significantly below the peak, reflecting the high volatility and speculative nature of the asset. The beta value is 2.01, meaning the stock exhibits twice the volatility of the broader market, suggesting that price movements will be amplified during periods of market stress or gains. These valuation metrics collectively paint a picture of a high-risk, high-volatility investment where traditional multiples are distorted by the negative earnings and the speculative nature of the late-stage drug development pipeline.
Growth & Income
The company achieved a revenue growth rate of 15.9% year-over-year, while earnings growth is N/A because the firm continues to operate at a loss. Since earnings are negative, they are technically growing at a slower rate than revenue in a mathematical sense, but practically, the company is not yet profitable enough to show a positive earnings growth percentage. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status indicates that the company reinvests all available earnings and cash reserves into growth initiatives, such as advancing the Entolimod candidate for acute radiation syndrome and other indications like neutropenia and lymphocyte exhaustion. The overall growth and income profile is defined by rapid revenue expansion in a niche market but a complete absence of income distribution, relying entirely on capital markets for future development funding. The 15.9% revenue growth suggests successful early commercialization or licensing deals, but the lack of earnings and dividends means all value creation is currently captured internally rather than returned to investors.